



| | | | |
|-------------------------|--------------------------------|---------------------------------|---------------------------|
| PATIENT NAME | Report, Sample | ACCESSION | 25042200004 |
| PATIENT DOB | Jan. 1, 2025 | ORDER CODE | GX25-0000444 |
| PATIENT GENDER | U | SAMPLE TYPE & SOURCE | Serum |
| PATIENT PHONE | (919) 313-9672 | COLLECTED | 04-21-2025, 09:01AM (EDT) |
| ACCOUNT | Mosaic Diagnostics | RECEIVED | 04-22-2025, 09:01AM (EDT) |
| PROVIDER | Test Provider | REPORTED | 04-22-2025, 09:02AM (EDT) |
| REPORT STATUS | FINAL | | |
| TEST INFORMATION | 2. Bartonella IgG Detect - IFA | DIAGNOSIS CODES | |

| QUALITATIVE RESULTS | | |
|---|--------|----------|
| | RESULT | FLAG |
| 4-SPECIES IFA SEROLOGY PANEL, IGG | | |
| Bartonella henselae IFA Serology, IgG | 1:256 | REACTIVE |
| Bartonella koehlerae IFA Serology, IgG | 1:256 | REACTIVE |
| Bartonella quintana IFA Serology, IgG | 1:256 | REACTIVE |
| Bartonella vinsonii berkhoffi IFA Serology, IgG | 1:256 | REACTIVE |

4-Species IFA Serology Panel, IgG: Test Result Interpretation

Reactive: A Bartonella species titer greater than or equal to 1:64 indicates the tested serum sample was reactive to the indicated Bartonella species antigen(s), and that the patient has been exposed to, or may presently be infected with, a Bartonella species.

Non-Reactive: IFA results with a Bartonella species titer of less than or equal to 1:32 indicates the tested serum sample was non-reactive with the indicated Bartonella species antigen(s).

Indeterminate: Unable to determine definitive reactivity status. Submission of an additional sample for repeat testing is recommended.

The expected ("Reference") value in the normal population is "Non-reactive" to Bartonella henselae, Bartonella quintana, Bartonella koehlerae, or Bartonella vinsonii berkhoffii. Serological results should be interpreted in the context of patient history, possible past exposure, other clinical findings, and laboratory results.

Research studies have shown that some bacteremic patients do not develop antibodies.

----- END OF REPORT -----

Tests included in this report were performed and analyzed at Galaxy Diagnostics. Reference laboratory test results may not be altered. These tests were developed and their performance characteristics determined by Galaxy Diagnostics. These tests have not been cleared or approved by the FDA. Galaxy Diagnostics (CLIA ID 34D2027997, Laboratory Director: Susan Orton, PhD, D(ABMLI)) is located at 6 Davis Drive, Suite 201, Research Triangle Park, NC.